"Aminophylline" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.
| Descriptor ID |
D000628
|
| MeSH Number(s) |
D02.092.782.258.368.050 D03.633.100.759.758.824.751.075 D26.310.048
|
| Concept/Terms |
Aminophylline- Aminophylline
- Theophylline Ethylenediamine
- Ethylenediamine, Theophylline
- Theophyllamine
|
Below are MeSH descriptors whose meaning is more general than "Aminophylline".
Below are MeSH descriptors whose meaning is more specific than "Aminophylline".
This graph shows the total number of publications written about "Aminophylline" by people in this website by year, and whether "Aminophylline" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aminophylline" by people in Profiles.
-
Aminophylline shortage and current recommendations for reversal of vasodilator stress: An ASNC information statement endorsed by SCMR. J Nucl Cardiol. 2019 Jun; 26(3):1007-1014.
-
Aminophylline shortage and current recommendations for reversal of vasodilator stress: an ASNC information statement endorsed by SCMR. J Cardiovasc Magn Reson. 2018 12 20; 20(1):87.
-
Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review. J Nucl Cardiol. 2018 02; 25(1):137-149.
-
Impact of a regimented aminophylline administration protocol on the burden of regadenoson-induced ischemia detected by SPECT myocardial perfusion imaging. J Nucl Cardiol. 2017 10; 24(5):1571-1578.
-
Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials. J Nucl Cardiol. 2015 Oct; 22(5):1008-18.
-
The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial. J Nucl Cardiol. 2014 Jun; 21(3):496-502.
-
Age and gender as predictors of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: a substudy of the ASSUAGE trial. Am J Ther. 2013 Nov-Dec; 20(6):622-9.
-
Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial. Int J Cardiovasc Imaging. 2013 Jun; 29(5):1029-37.
-
Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial". J Nucl Cardiol. 2012 Jun; 19(3):448-57.